0001062993-24-010183.txt : 20240514 0001062993-24-010183.hdr.sgml : 20240514 20240514163330 ACCESSION NUMBER: 0001062993-24-010183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240510 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Strydonck, Gerald E. CENTRAL INDEX KEY: 0001748247 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 24945012 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVENUE CITY: ROCHESTER STATE: NY ZIP: 14620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-05-10 0001205922 VACCINEX, INC. VCNX 0001748247 Van Strydonck, Gerald E. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 1 0 0 0 0 Common Stock 2024-05-10 4 A 0 543 5.75 A 543 D Stock Option (Right to Buy) 204.0 2027-09-15 Common Stock 426 426 D Stock Option (Right to Buy) 78.9 2029-03-30 Common Stock 166 166 D Stock Option (Right to Buy) 116.7 2020-05-15 Common Stock 514 514 D Stock Option (Right to Buy) 82.8 2029-06-29 Common Stock 159 159 D Stock Option (Right to Buy) 107.55 2029-09-27 Common Stock 123 123 D Stock Option (Right to Buy) 72.75 2029-12-28 Common Stock 182 182 D Stock Option (Right to Buy) 59.25 2021-05-14 Common Stock 1045 1045 D Stock Option (Right to Buy) 32.25 2022-05-11 Common Stock 1905 1905 D Stock Option (Right to Buy) 16.8 2023-05-12 Common Stock 3550 3550 D Stock Option (Right to Buy) 6.15 2024-05-11 Common Stock 9589 9589 D Stock Option (Right to Buy) 5.75 2024-05-10 4 A 0 10108 0 A 2025-05-10 Common Stock 10108 10108 D Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024. Exercisable in full as of the date of this report. This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. All figures in this Form 4 reflect the Issuer's 1-for-14 reverse stock split effected on February 19, 2024. /s/ Maurice Zauderer, Attorney-in-Fact for Gerald E. Van Strydonck 2024-05-14